NCT05568706Phase 2Completed

A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.

Study sponsor: Enanta Pharmaceuticals, Inc · ENTA

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2025-06-23Actual

Enrollment · participants187Actual

Source updated2026-08-19Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-07-16 · 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording

− Before

Measure: Time to ~~resolution~~ of RSV Lower Respiratory Tract Disease (LRTD) ~~symptoms~~

+ After

Measure: Time to Resolution of RSV Lower Respiratory Tract Disease (LRTD) Symptoms Measure: Time to Complete Resolution of LRTD Symptoms for the mITT Population Measure: Time to Complete Resolution of LRTD Symptoms for the HR3 Population

Actual enrollment increased by 1 participants

− Before

~~186 participants (actual)~~

+ After

187 participants (actual)

Check registry source

Study details

Conditions studied

RSV Infection

Treatments or interventions studied

EDP-938Drug
PlaceboDrug

Primary outcomes · main study measures

Read the study measures

measure: Time to Resolution of RSV Lower Respiratory Tract Disease (LRTD) Symptoms; description: Resolution of LRTD Symptoms is defined as the first of two consecutive timepoints where each of the four LRTD symptoms (cough, short of breath, wheezing and coughing up phlegm\[sputum\]) as assessed by RiiQTM Scale Score is zero or 1. Time to resolution of LRTD symptoms is calculated as: date/time of resolution - date/time of first dose with conversion to days.; timeFrame: Day 1 through Day 33; measure: Time to Complete Resolution of LRTD Symptoms for the mITT Population; description: Complete resolution of LRTD Symptoms is defined as the first of two consecutive timepoints where each of the four LRTD symptoms (cough, short of breath, wheezing and coughing up phlegm\[sputum\]) as assessed by Respiratory Infection Intensity and Impact Questionnaire (RiiQ) Scale Score is zero. Time to complete resolution of LRTD symptoms is calculated as: date/time of complete resolution - date/time of first dose with conversion to days.; timeFrame: Day 1 through Day 33; measure: Time to Complete Resolution of LRTD Symptoms for the HR3 Population; description: Complete resolution of LRTD Symptoms is defined as the first of two consecutive timepoints where each of the four LRTD symptoms (cough, short of breath, wheezing and coughing up phlegm\[sputum\]) as assessed by RiiQTM Scale Score is zero. Time to complete resolution of LRTD symptoms is calculated as: date/time of complete resolution - date/time of first dose with conversion to days.; timeFrame: Day 1 through Day 33

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history